Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia

References

• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–11208. doi:10.1056/NEJMoa130680124670166
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–e111.27418577
   PubMed Web of Science ®Google Scholar
• Chou CC, Shen CF, Chen SJ, et al. Infectious Diseases Society of Taiwan; Taiwan Society of Pulmonary and Critical Care Medicine, Medical Foundation in Memory of Dr. Deh-Lin Cheng;; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education;; CY Lee’s Research Foundation for Pediatric Infectious Diseases and Vaccines,; 4th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group. Recommendations and guidelines for the treatment of pneumonia in Taiwan. J Microbiol Immunol Infect. 2019;52:172–99. doi:10.1016/j.jmii.2018.11.00430612923
   PubMedGoogle Scholar
• Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol. 2012;33:250–256. doi:10.1086/66404922314062
   PubMed Web of Science ®Google Scholar
• Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51:S81–7. doi:10.1086/65305320597676
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, Phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18:285–295. doi:10.1016/S1473-3099(17)30747-829254862
   PubMed Web of Science ®Google Scholar
• Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19:1299–1311. doi:10.1016/S1473-3099(19)30403-731563344
   PubMed Web of Science ®Google Scholar
• MacVane SH. Antimicrobial resistance in the intensive care unit: a focus on gram-negative bacterial infections. J Intensive Care Med. 2017;32:25–37. doi:10.1177/088506661561989526772199
   PubMed Web of Science ®Google Scholar
• Kaye KS, Pogue JM. Infections caused by resistant gram-negative bacteria: epidemiology and management. Pharmacotherapy. 2015;35:949–962. doi:10.1002/phar.163626497481
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen CC, Lu YC, Lin TP, Chuang YC, Tang HJ. Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms. Infect Drug Resist. 2018;11:1441–1445. doi:10.2147/IDR.S17525730237728
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen CC, Lu YC, Chuang YC, Tang HJ. In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Infect Drug Resist. 2019;12:25–29. doi:10.2147/IDR.S18120130588045
   PubMed Web of Science ®Google Scholar
• Sheu MJ, Chen CC, Lu YC, et al. In vitro antimicrobial activity of various cefoperazone/sulbactam products. Antibiotics (Basel). 2020;9(2):77. doi:10.3390/antibiotics9020077
   Web of Science ®Google Scholar
• Patankar M, Sukumaran S, Chhibba A, Nayak U, Sequeira L. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections. J Assoc Physicians India. 2012;60:22–24.
   Google Scholar
• Sader HS, Carvalhaes CG, Streit JM, Castanheira M, Flamm RK. Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America. Int J Infect Dis. 2020;91:32–37. doi:10.1016/j.ijid.2019.11.00631715325
   PubMed Web of Science ®Google Scholar
• Xia J, Zhang D, Xu Y, Gong M, Zhou Y, Fang X. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam. Int J Infect Dis. 2014;23:90–93. doi:10.1016/j.ijid.2014.01.01724726664
   PubMed Web of Science ®Google Scholar
• Liu JW, Chen YH, Lee WS, et al. Randomized noninferiority trial of cefoperazone-sulbactam versus cefepime in the treatment of hospital-acquired and healthcare-associated pneumonia. Antimicrob Agents Chemother. 2019;63:e00023–19. doi:10.1128/AAC.00023-1931138577
   PubMed Web of Science ®Google Scholar
• Xin X, Jian L, Xia X, et al. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections. Ann Clin Microbiol Antimicrob. 2013;12:38. doi:10.1186/1476-0711-12-3824321187
   PubMed Web of Science ®Google Scholar
• Liu WD, Shih MC, Chuang YC, Wang JT, Sheng WH. Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia. J Microbiol Immunol Infect. 2019;52:788–795. doi:10.1016/j.jmii.2019.04.00831155463
   PubMedGoogle Scholar
• Chao CM, Chen CC, Huang HL, Chuang YC, Lai CC, Tang HJ. Clinical experience of patients receiving doripenem-containing regimens for the treatment of healthcare-associated infections. PLoS One. 2016;11:e0167522. doi:10.1371/journal.pone.016752227907197
   PubMed Web of Science ®Google Scholar
• Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184:1409–1417. doi:10.1164/rccm.201102-0349OC21920919
   PubMed Web of Science ®Google Scholar
• Ismail B, Shafei MN, Harun A, Ali S, Omar M, Deris ZZ. Predictors of polymyxin B treatment failure in Gram-negative healthcare-associated infections among critically ill patients. J Microbiol Immunol Infect. 2018;51:763–769. doi:10.1016/j.jmii.2017.03.00728716359
   PubMedGoogle Scholar
• Jean SS, Liao CH, Sheng WH, Lee WS, Hsueh PR. Comparison of commonly used antimicrobial susceptibility testing methods for evaluating susceptibilities of clinical isolates of Enterobacteriaceae and nonfermentative gram-negative bacilli to cefoperazone-sulbactam. J Microbiol Immunol Infect. 2017;50:454–463. doi:10.1016/j.jmii.2015.08.02426454423
   PubMedGoogle Scholar
• Chang PC, Chen CC, Lu YC, et al. The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms. J Microbiol Immunol Infect. 2018;51:207–213. doi:10.1016/j.jmii.2017.08.02629037802
   PubMedGoogle Scholar
• Cai Z, Yang W, He Y, et al. Cefoperazone/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding: a case report and review of the literature. Drug Saf Case Rep. 2016;3:2. doi:10.1007/s40800-016-0025-927747682
   PubMedGoogle Scholar
• Hu HR. Fatal Vitamin K-dependent coagulopathy associated with cefoperazone/sulbactam: a case report. Drug Saf Case Rep. 2019;6:6. doi:10.1007/s40800-019-0100-031201572
   PubMedGoogle Scholar
• Wang W, Liu Y, Yu C, et al. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study. Expert Opin Drug Saf. 2020;19:339–347. doi:10.1080/14740338.2020.171309031914329
   PubMed Web of Science ®Google Scholar